vTv Therapeutics Inc.
NASDAQ:VTVTBiotechnology
+$0.50 today
- Market cap
- $64.17M
- Beta
- 0.27
- P/E (TTM)
- 128.7
- EPS (TTM)
- $0.27
Volume 0.02M
Average 0.05M
VTVT Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
vTv Therapeutics Inc.NASDAQ: VTVT
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization declines year over year
Q1 FY2026 depreciation & amortization of $1K fell 88.9% year over year, ahead of the -89.5% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 50.0% from the prior quarter. Over 3 fiscal years it compounded at -44.2% a year.
Context
- Depreciation & amortization increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of -88.9% holds above the trailing-twelve-month pace of -89.5%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 16K USD
- Year-over-year change
- -82.0%
- 4-year CAGR
- -34.9%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 16K | -82.0% |
| FY2024 | 2024-12-31 | 89K | -1.1% |
| FY2023 | 2023-12-31 | 90K | -2.2% |
| FY2022 | 2022-12-31 | 92K | +3.4% |
| FY2021 | 2021-12-31 | 89K | — |
Depreciation & Amortization vs competitors
How VTVT compares with its peers on the latest reported figures
- VTVT's LTM Mar 2026 depreciation & amortization of $8K is the smallest of the 9 companies compared; the peer median is $1.98M.
- Its year-over-year change of -89.5% is the lowest of 9, against a peer median of +366.5%.
- Depreciation & amortization amounts to 0.0% of revenue for VTVT, versus a peer median of 15.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
OSTXOS Therapies Incorporated | LTM Mar 2026 | $363.33M | +106428.1% | +7569.0% | — |
| LTM Mar 2026 | $181.73M | +85472.1% | +14.3% | — | |
| LTM Mar 2026 | $5.17M | +4.4% | -20.7% | 7.8% | |
| LTM Jun 2026 | $3.65M | +111.3% | +14.0% | 17.4% | |
| LTM Mar 2026 | $305K | +6000.0% | +229.4% | 13.3% | |
| LTM Mar 2026 | $267K | +621.6% | -34.3% | — | |
| LTM Mar 2026 | $119.64K | +3.7% | -17.0% | 35.9% | |
| LTM Mar 2026 | $94.69K | +12.5% | +13.6% | — | |
| LTM Mar 2026 | $8K | -89.5% | -44.2% | 0.0% | |
| Peer median (excluding VTVT) | $1.98M | +366.5% | +13.8% | 15.3% | |
Competitors are the stored peer set for VTVT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (17.73M) | (19.16M) | (20.25M) | (22.71M) | (31.08M) |
| Depreciation & Amortization | 89K | 92K | 90K | 89K | 16K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 2.36M | 0 | 1.58M | 2.76M | 3.78M |
| Change in Working Capital | 35K | 5.39M | 4.39M | (5.44M) | 1.89M |
| Accounts Receivables | 101K | (116K) | 71K | 40K | 0 |
| Inventory | (889K) | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.83M | (856K) | 2.93M | 0 | 1.53M |
| Other Working Capital | (1.01M) | 6.36M | 1.39M | (5.48M) | 362K |
| Other Non-Cash Items | (4.06M) | (1.56M) | (4.89M) | (10K) | 142K |
| Operating Cash Flow | (19.31M) | (15.25M) | (19.08M) | (25.31M) | (25.26M) |
| Capital Expenditures | 0 | (21K) | 0 | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 4.4M | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 4.4M | 0 | 0 |
| Other Investing Activities | 0 | 0 | (4.4M) | 0 | 0 |
| Investing Cash Flow | 0 | (21K) | 4.4M | 0 | 0 |
| Debt Repayment | 172K | (808K) | (33K) | (191K) | (392K) |
| Common Stock Issued | 26.76M | 14.79M | 12.03M | 52.8M | 77.48M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 47K | 0 | 0 | 0 | 341K |
| Financing Cash Flow | 26.98M | 13.98M | 12M | 52.61M | 77.44M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 7.67M | (1.29M) | (2.68M) | 27.3M | 52.19M |
| Free Cash Flow | (19.31M) | (15.27M) | (19.08M) | (25.31M) | (25.26M) |
vTv Therapeutics Inc.
NASDAQ:VTVT
Intrinsic Alpha fair value
Locked
Current Price
$16.23
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.